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SYNERGY OF BCL2 AND HISTONE DEACETYLASE INHIBITION AGAINST 
LEUKEMIC CELLS FROM CUTANEOUS T-CELL LYMPHOMA PATIENTS. 
Benoit Cyrenne, Julia Lewis, Jason Weed, Kacie Carlson, Fatima Mirza, 
Francine Foss, and Michael Girardi. Department of Dermatology, Yale University, 
School of Medicine, New Haven, CT. 
 
The presence and degree of peripheral blood involvement in patients with 
cutaneous T-cell lymphoma (CTCL) portend a worse clinical outcome. Available 
systemic therapies for CTCL may variably decrease tumor burden and improve 
quality of life, but offer limited effects on survival; thus, novel approaches to the 
treatment of advanced stages of this non-Hodgkin lymphoma are clearly 
warranted. Mutational analyses of CTCL patient peripheral blood malignant cell 
samples suggested the anti-apoptotic mediator BCL2 as a potential therapeutic 
target. To test this, we developed a screening assay for evaluating the sensitivity 
of CTCL cells to targeted molecular agents, and compared a novel BCL2 
inhibitor, venetoclax, alone and in combination with a histone deacetylase 
(HDAC) inhibitor, vorinostat or romidepsin. Peripheral blood CTCL malignant 
cells were isolated from 25 patients and exposed ex vivo to the three drugs alone 
and in combination, and comparisons were made to four CTCL cell lines (Hut78, 
Sez4, HH, MyLa). The majority of CTCL patient samples were sensitive to 
venetoclax, and BCL2 expression levels were negatively correlated (r=-0.52, 
P=.018) to IC50 values. Furthermore, this anti-BCL2 effect was markedly 
potentiated by concurrent HDAC inhibition with 93% of samples treated with 
venetoclax and vorinostat and 73% of samples treated with venetoclax and 
romidepsin showing synergistic effects. These data strongly suggest that 
concurrent BCL2 and HDAC inhibition may offer synergy in the treatment of 
patients with advanced CTCL. By using combination therapies and correlating 
response to gene expression in this way, we hope to achieve more effective and 
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Diagnosis, Prognosis, and Current Therapies 
Cutaneous T-cell lymphoma (CTCL) is a rare form of non-Hodgkin 
lymphoma of the skin-homing CD4+ memory T-cells. CTCL is a group of 
malignancies with a variety of clinical manifestations, the majority of which may 
be categorized along the mycosis fungoides (MF) and Sézary syndrome 
spectrum. The overall annual incidence of CTCL in the United States is 6.4 cases 
per million persons, as calculated using Surveillance, Epidemiology, and End 
Results (SEER) registry data.1 CTCL makes up 71% of all primary cutaneous 
lymphoma cases and the remaining 29% are predominantly B-cell derived 
neoplasms.2,3 In its early stages, mycosis fungoides (MF) is typically an indolent 
disease characterized by localized skin patches, plaques and tumors, comprising 
of 50% of all CTCL cases. In contrast, Sézary syndrome (SS) is a more 
aggressive form of CTCL presenting with erythroderma, and frequently, 
involvement of the lymph nodes, spleen, and liver. As the disease progresses, 
new lesions may spread, and existing lesions may enlarge in both size and 
thickness. In advanced disease, such as leukemic CTCL, malignant T-cells may 
predominate the peripheral lymphocyte compartment, or invade the viscera.4 In 
cases of advanced disease the loss of the normal T-cell receptor (TCR) diversity 
leads to significant immunosuppression, leading to a high incidence of 




 Diagnosing CTCL has been a consistent struggle for physicians and 
patients since it was first described in 1806. While classically MF presents as 
well demarcated patches involving sun-protected skin in a “bathing-suit” 
distribution, there is significant overlap in clinical features with benign 
dermatoses, such as eczema or psoriasis.4,6 Additionally, there may be 
alterations in pigmentation—either hypo- or hyper-pigmentation—and changes in 
hair growth patterns, such as alopecia.4,6 Initial diagnosis thus relies on biopsy. 
Histologically, MF is characterized by epidermotropism with Pautrier’s 
microabscesses; but much like the clinical picture, the findings on biopsy show 
high degree of variability, and may resemble benign inflammatory disorders such 
as pityriasis lichenoides, granuloma annulare, gyrate erthema, or lichen planus. 
This ambiguity in biopsy results frequently leads to the need for multiple biopsies 
and a delayed diagnosis, taking an average of 6 years from the initial 
presentation.7  
 This uncertainty in both clinical and histopathological diagnoses has led to 
the development of more sensitive and specific tests. CTCL features a T-cell 
clone which may be detected via polymerase chain reactions (PCR) of the T-cell 
receptor within the skin (i.e. fresh, frozen, or formalin-fixed paraffin-embedded 
biopsy specimens), the peripheral blood, or lymph node. This test, however, has 
limited utility due to the low concentration of malignant cells, leading to false-
negatives and the frequent presence of oligoclonal expansion in other 
inflammatory disorders, resulting in false positives.7–10 Despite these limitations, 




specific diagnostic test for MF.7,11 Newer techniques to assess T-cell clonality 
such as high throughput sequencing show improved sensitivity for detection of 
malignancy.6,7,12 The rapid identification of CTCL upon presentation is essential 
to improving clinical outcomes, as increased length of time to diagnosis 
correlates with decreased survival.13  
 The identification of the prototypical Sézary cells, with their distinct 
cerebriform nuclei, was initially the essential diagnostic test for blood 
involvement, and remains within the 2007 update of the International Society for 
Cutaneous Lymphomas (ISCL) and the European Organization for Research and 
Treatment of Cancer (EORTC) guidelines for diagnosis and staging of CTCL.14 
The ability to identify the cell surfaces markers of circulating T-cells, specifically 
with the phenotype CD4+ CD7- and/or CD26-, on peripheral blood flow cytometry 
has improved identification of peripheral malignant T-cell populations. Flow 
cytometry has also proved useful in the identification of clonality via the 
quantification of TCR β chain variable region (TCR-Vβ) family usage.15,16 The 
practical application of TCR-Vβ analysis is hindered by the high degree of 
variability among expression TCRs, and the limited number of Vβ antibodies 
present in commercial assays, though the absence of Vβ reactivity to a given 
assay can also be used as an indirect marker of clonality.17 Gibson et al. propose 
new criteria for staging of blood involvement that includes tests for clonality such 
as the aforementioned TCR-PCR and TCR-Vβ flow cytometry analysis.18 
The rapid and accurate diagnosis of CTCL in the skin and blood is critical 




stage IA, have similar life expectancies as the general population a 5-year 
survival rate of 94-100%, blood and lymph node involvement are independent 
predictors of poor survival outcomes.19–21 In advanced stages, CTCL is a fatal 
disease that is incurable with conventional therapies, with a 0-18% 5- year 
survival rate among stage IV-B patients.20,22 Additional factors associated with 
worse prognosis include elevated lactate dehydrogenase, increased age, large 
cell transformation, degree of peripheral blood involvement, and the 
folliculotropic-MF variant.  
While other lymphoproliferative diseases, such as ALL or CLL, may be risk 
stratified by cytogenetic findings, no similar criteria exists in CTCL. Extensive 
work has been performed to identify patterns in genetic alterations and 
expression that correlate to worse survival. Cluster analysis of genetic 
expression from skin biopsies of CTCL patients led to the identification of three 
patient clusters consisting of earliest stage disease (stages I-A and I-B), more 
extensive disease (stages I-B and III), and tumor type disease (stage IIB), of 
which the two latter clusters were associated with worse treatment response and 
survival.23,24  
Treatment strategies for CTCL are as heterogeneous as the disease itself. 
The site of disease and the degree of involvement, as well as patient and 
physician preference will largely dictate the specific prescribed course. For skin-
limited disease such as MF, skin-directed treatments are preferred, such as high 
potency topical corticosteroids, phototherapy, nitrogen mustard-based therapies 




plaque, tumor, and/or leukemic CTCL, systemic therapies are indicated. These 
include extracorporeal photopheresis, interferon-base therapies, bexarotene, and 
methotrexate. With rare exceptions in cases of hematopoietic cell 
transplantation,25 the overall response rates for novel agents including retinoids, 
HDAC inhibitors, and pralatrexate range from 30-50% and are generally not 
durable.26 There remains an unmet medical need for new and more effective 
treatments, which the work of this thesis aims to address. 
 
Genetic Alterations in CTCL 
 Recent studies5,27–30 have made significant strides in our understanding of 
the molecular pathogenesis of CTCL, most notably via exome sequencing and 
expression analysis. These analyses have shown a predominance of gene copy 
number alterations (GCNA) over single nucleotide variant (SNV) mutations, 
without evidence of common chromosomal translocations. The preponderance of 
GCNAs among CTCL patients indicates a significant degree of chromosomal 
instability. Although Döbbeling et al. found both CTCL patient samples and cells 
lines to lack expression of recombination-activating genes (RAG), the high 
frequency of focal deletions observed suggest possible involvement of RAG 
proteins which cause breakpoints in DNA via endonuclease-mediated cleavage, 
and are necessary for V(D)J (V, variability; D, diversity; J, joining) 
recombination.5,31 RAG cleavage sites can be identified by the presence of RAG 
heptamers, which were found adjacent to greater than 12% of CTCL deletions.5 




leads to disordered mitosis, and high rates of double-stranded DNA breaks. 
Several germ cell proteins were found to be highly expressed in CTCL cells 
relative to healthy memory T-cells, and may be responsible for or associated with 
severe chromosomal instability– in particular, cancer testis genes responsible for 
the initiation of meiosis, strand breaks and subsequent homologous 
recombination and the formation of synaptonemal complexes.32,33 
Other mutations in genes involved in DNA repair and genome 
maintenance–such as POT1, ATM, and BRAC2–have also been identified as 
occurring in SS patients, and may also contribute to the high degree of genetic 
variability in CTCL.34 ATM and POT1 are involved in telomere maintenance and 
their derangement may lead to the telomere shortening observed in CTCL. 
Catastrophic telomere shortening may also lead to chromothripsis, and near-
global chromosomal changes, such as those observed in CTCL patient cells.35,36 
 SNV mutations, which comprise of <10% of all driver mutations in CTCL, 
are also of interest in the pathogenesis of CTCL. The number of patients 
examined via exome sequencing and expression analysis limits power in genetic 
studies, which require cohorts including a minimum of 200 samples for accurate 
and complete identification.37 Despite these limitations, point mutations have 
been put forth as likely driver mutations, including within CD28.  Alternatively, 
genetic shuffling may result in a fusion product, for example, the CD28-CTLA4 
protein that can cause constitutive activation of T-cells.38 Other common 
mutations observed in CTCL patient cohorts include RHOA, BRAF, STAT5B, 




suggests that the number of SNV driver mutations is greater than previously 
reported. Among these are 5 genes not previously associated with another 
malignancy: ARHGEF3, CSNK1A1, RLTPR, PTPRN2, and RARA.37  
The categories of genetic alterations include changes in the behavior of 
the malignant T-cell population and their imprint on the immune system, which 
suggest clustering under three major pathways: constitutive T-cell activation (e.g. 
STAT3, STAT5B, CARD11, CD28); resistance to apoptosis/cell cycle 
dysregulation (e.g. MYC, FAS, CDKN2A, TP53, RB1); and DNA structural 
dysregulation/chromatin remodeling or repair (e.g. ARID1A, DNMT3A) (Figure 1).  
 
Figure 1: Pathways of the identified driver genetic alterations in CTCL 
identified by exome sequencing. Genetic alterations in CTCL can grouped in 
three categories: T-cell activation, cell cycle release/apoptosis inhibition, and 
chromatic remodeling. Credit: Michael Girardi. 
 
With this wellspring of new information, recently discovered and re-
purposed agents targeting pathways or specific gene mutations may be screened 
as a patient-specific treatment algorithm is developed. With 30% of drugs in 




new molecular therapies allows us to leverage established safety profiles to fast-
track new treatment options for patients.39  
 
Inhibition of Apoptosis, BCL2, and Venetoclax 
One such opportunity for the repurposing of existing therapies involves the 
dysregulation of B cell lymphoma-2 (BCL2) driven apoptotic pathways in CTCL. 
The BCL2 family of proteins is a critical group of proteins involved in the 
regulation of apoptosis. These proteins further regulate autophagy via the binding 
of Beclin-1.40 BCL2 proteins are part of the intrinsic, or mitochondrial, apoptosis 
pathway in which an apoptotic signal such as damage from free radicals or 
growth factor starvation leads to programmed cell death (i.e. apoptosis) via 
caspase activation. The apoptotic signal leads, via BCL2 family proteins, to the 
permeabilization of the outer mitochondrial membrane, the release of cytochrome 
c, and the subsequent activation of caspase.41,42 This is in contrast to the 
extrinsic apoptotic pathway, in which death receptors activated by signals, such 
as FAS-ligand or TNF-α, lead to caspase activation, or the perforin/granzyme 
pathway, which leads to cell death by either caspase activation (granzyme B) or, 
independent of capase, via direct DNA damage (granzyme A).43,44  
The BCL2 family is traditionally defined by the presence of conserved 
residue sequences known as BCL2 homology (BH) motifs, of which there are 
four (BH1-4), though more recent findings suggests that BH motifs are not 
essential to the function or characterization of BCL2 family proteins.45,46 The 




BCL2, BCL-XL, MCL1, BCL-w), the multiregion pro-apoptotic proteins (e.g. BAX, 
BAK, BIK, BID) which are composed of multiple BH motifs, and the BH3-only pro-
apoptotic proteins (e.g. BIM, BAD, NOXA, HRK, BLK, BMF, PUMA).41 The BH3-
only proteins may act in two ways: as a sensitizer, in which they bind to anti-
apoptotic proteins, or as activators, which may bind to either anti-apoptotic 
proteins or the multiregion pro-apoptotic proteins.47 Twenty-five BCL2 family 
proteins have been discovered to date.48  
Anti-apoptoic proteins such as BCL2 or BCL-XL are mitochondrial-
membrane bound or membrane bound upon activation. These proteins bind and 
sequester the BH3- only pro-apoptotic proteins such as BIM. In the presence of a 
death signal, the sensitizer BH3-only pro-apoptotic proteins (such as BMF) bind 
to anti-apoptotic proteins (such as BCL2) releasing activator BH3-only pro-
apoptotic proteins (such as BIM). These proteins then in turn bind to multi-
domain, pro-apoptotic proteins (such as BAX or BAK) which oligomerize to form 
pores in the mitochondrial membrane, resulting in the release of cytochrome c 
and caspase activation. The activation or inhibition of apoptosis depends on the 
specific ratios of pro- and anti- apoptotic proteins.41  
CTCL cells exhibit a high degree of resistance to apoptosis, even in the 
presence of programmed-cell death inducing signals, and, as described above, 
CTCL cells exhibit multiple genetic alterations which explain this behavior. Four 
of the common gene alterations identified in CTCL are STAT3 amplifications, 
STAT5B amplifications, and P53 deletions; the frequency of which was 




11-gene FISH panel.49 Each of these mutations has been linked to the inhibition 
of apoptosis through the up-regulation of BCL2 transcription, in turn leading to 
increased BCL2 activity and dependence.50–57 Additionally point mutations have 
been identified in the ITPR1 gene, which is associated with increased risk of 
breast cancer, and involved in BCL2 activity and regulation.58 The tendency of 
CTCL towards inhibition of apoptosis, and the putative trend towards increased 
BCL2 activity in CTCL, makes inhibition of BCL2 an attractive therapeutic target.  
 
 
Figure 2: Genetic alterations in CTCL, leads to increased BCL2 activity, and 
resistance to apoptosis. STAT3 amplifications, STAT5B amplifications, P53 
deletions, and Fas alterations result in decreased apoptosis.  
 
Venetoclax (ABT-199) is a BH3-mimetic, BCL2 selective inhibitor without 
additional cross-reactivity with BCL-XL, BCL-W, or MCL1.59 Venetoclax (ABT-
199) is a unique agent as a BCL2 inhibitor due to its specificity. Other so-called 
“BCL2 inhibitors” available for research purposes are not specific for BCL2 as 




of these inhibitors was navitoclax (ABT-263) which showed impressive pre-
clinical data in BCL2 dependent lymphoid malignancies. Further clinical 
development of navitoclax was restricted due to dose-limiting thrombocytopenia 
as a result of additional inhibition of BCL-XL, which is essential for platelet 
survival. ABT-263 was thus re-engineered to bind exclusively to the BCL2 
binding pocket, and clinical trials have borne out its potent efficacy in the 
inhibition of BCL2. Venetoclax was first approved by the U.S. FDA in 2016, 
received accelerated approval for the treatment of relapsed or refractory CLL 
with 17p deletion, and is the only BCL2 inhibitor that has received approval by 
the U.S. FDA for clinical use.60 Venetoclax is also currently undergoing trials for 
follicular lymphoma, diffuse large B cell lymphoma, acute myeloid leukemia, 
multiple myeloma, Waldenstrom macroglobulinemia, and NHL (excluding CTCL).  
 
Figure 3: Mechanism of action of venetoclax (ABT-199). Venetoclax, as a 
BH3 mimetic, binds with high affinity to BCL2, and causing dissociation of the 
BCL2-BIM complex. BIM is then able to activate the pro-apoptotic protein BAX, 
leading to oligomerization of BAX, permeabilization of the mitochondrial 




The potential for BCL2 inhibition in the treatment of CTCL may extend 
beyond its use as a monotherapy. Combined inhibition of BCL2 members and 
HDACs has shown synergistic effects in CTCL61 and other malignancies, 
including mantle cell lymphoma62 and glioblastoma.63 Romidepsin and vorinostat 
are HDAC inhibitors64 which have widespread effects including modulation of 
gene expression, induction of cellular differentiation, and modulation of apoptosis 
effector genes.65 One mechanism of action of apoptosis is via alterations in the 
expression of the intrinsic apoptosis pathway, namely the BCL2 family genes,66–
69 including upregulation of pro-apoptotic factors such as BID and BIM, and down 
regulation of the anti-apoptotic factors such as BCL-XL and MCL1.70–72  
Through in vitro testing of CTCL patient-derived blood samples, we 
demonstrate the potential of BCL2 inhibition by venetoclax as a novel treatment 
for CTCL. Furthermore, we reveal that this effect is synergistically potentiated via 
HDAC inhibition afforded by romidepsin or vorinostat. These results suggest that 
BCL2 inhibition, alone or in combination with HDAC inhibition, represents a 






Statement of Purpose 
Validate BCL2 as a potential target for the treatment of CTCL 
 Prior to my arrival in the Girardi Lab, Jason Weed (YSM 2017) led efforts 
in designing and implementing an in vitro targeted dry testing platform for 
leukemic CTCL, leading to the identification of several candidate drugs for further 
testing, the most promising among which was venetoclax. We aim to test the in 
vitro sensitivity of venetoclax on an expanded patient cohort in order to validate 
BCL2 as a potential therapeutic target.   
 
Associate expression of BCL2 family genes to the in vitro patient sample 
sensitivity to venetoclax 
In order to validate the putative mechanism of action of venetoclax in the 
killing of CTCL cells—inhibition of BCL2—we sought to associate genetic 
expression of BCL2 and other BCL2 family members to the sensitivity of 
venetoclax.  Additionally we sought to identify ratios of expression of BCL2 family 
members that predict sensitivity to venetoclax.  
 
Identify synergistic combinations of therapies 
We hypothesize that drugs which alter genetic expression of BCL2 family 
members, such as the HDAC inhibitors, vorinostat and romidepsin, will synergize 
with venetoclax for more efficient killing of CTCL cells, with the hope that in 
clinical practice, such combinations will limit both resistance and systemic 







Blood samples were obtained from CTCL patients at the Yale Cancer 
Center, receiving treatment either at the Yale Photopheresis Center or at the 
Yale-New Haven Hospital Smilow Cancer Hospital. Written informed consent 
was obtained from all subjects in accordance with the Yale Human 
Investigational Review Board. Approximately 45 mL of peripheral blood was 
obtained from consenting patients and healthy donors and collected in lithium 
heparin tubes (BD Vacutainer). The whole blood was diluted in a 3:1 ratio with 
phosphate-buffered saline (PBS), and peripheral blood mononuclear cells 
(PBMC) were separated from whole blood using SepMateTM. 15 mL of Ficoll (GE 
Healthcare Ficoll-Paque Premium) was placed at the bottom of SepMateTM-50 
tubes and diluted blood was layered on top. The SepMateTM-50 tubes were then 
centrifuged for 20 minutes at 1200g at room temperature. Buffy coats were 
isolated and washed with PBS with 2% fetal bovine serum (FBS) in 15 mL 
conical tubes, centrifuged for 8 minutes at 300g at room temperature, 
resuspended in PBS with 2% FBS, rewashed in PBS with 2% FBS and 
centrifuged again for 8 minutes at 300g at room temperature to minimize residual 
Ficoll. The pellet was then re-suspended in RPMI and counted using 
hemocytometer.  CD4+ T-cells were selected by Miltenyi Biotec (Bergisch 
Gladbach, Germany) MACS CD4+ negative selection kit per the manufacturer’s 




depending on the known aberrant phenotype of the patient, as measured by the 
patient’s most recent peripheral blood flow cytometry.  
Aliquots of unfractionated PBMC and purified samples were obtained to 
assess purity and verify expression of phenotypic markers. Additional aliquots of 
purified samples (minimum 500 000 cells) were obtained and lyzed for RNA 
analysis using Qiagen RNEasy (see below). Following isolation, cells were 
cultured in RPMI 1640 medium supplemented with 10% heat-inactivated FBS, 
glutamine (2mM), penicillin (100μ/mL), and streptomycin (100μg/mL), as well as 
IL2 (10ng/mL), IL7 (5ng/mL), IL15 (10ng/mL), and IL13 (10ng/mL; all cytokines 
from R&D Systems) at 37°C, 5% CO2, and 95% humidity. 
 
Cell Viability Assay 
Following isolation of the desired cell population, cells were incubated in 
quadruplicate at a density of 100cells/μL in 100μL of media, for a total of 105 
cells/well, in a black optical 96-well plate. In order to limit effects from uneven 
evaporation across the plate, cells were not plated in the exterior two rows of 
wells, and instead filled with 100 μL of media. In order to ensure an equal 
concentration of cells across the plate, cells were continuously mixed using 
gentle pipetting throughout the plating process.  
 Cells were incubated for 72 hours with venetoclax (3 nM to 100 µM), 
romidepsin (0.1 nM to 10 nM), and/or vorinostat (0.1 µM to 10µM). The CellTiter-
Glo® Luminescent Cell Viability Assay (Promega, WI, USA) was used to 




present. Plates were read using the Perkin Elmer Victor Light Luminescence 
Counter (Waltham, MA, USA). Drug concentrations were applied in approximate 
half-log10 increments to patient samples, and in 2-fold increments for cell lines. 
Cell luminescence was normalized to a vehicle control containing 0.2% DMSO 
and corrected for media. 
Stocks of 50nM venetoclax, 20mM vorinostat, and 20nM romidepsin from 
ApexBio (Houston, TX, USA) were prepared in DMSO and stored at -20°C. 
Campthothecin (10μM) from Sigma (St. Louis, MO, USA) was used a positive 
control for both the Viability Assay and the Caspase-3/7 Assay.  
 
Caspase-3/7 Assay  
Patient samples were incubated for 1-48  hours as described above in the 
Cell Viability Assay. Following incubation, the Promega Caspase-Glo® 3/7 assay 
(Madison, WI, USA) was used to quantitate caspase activity, as per the 
manufacturer’s protocol. Plates were read using a Perkin Elmer Victor X Light 
Luminescence Counter. 
 
Flow Cytometry Analysis  
Unfractionated PBMC and isolated malignant T-cell populations were 
analyzed using flow cytometry. All samples were matched with an isotype 
control. The following monoclonal antibodies were included: CD3 from BD 
Biosciences (San Jose, CA, USA); CD4, CD7, and CD26 from eBioscience (San 




were blocked with human TruStain FcX™ from BioLegend (San Diego, CA, USA) 
for 10 minutes then incubated with selected antibodies for 20min at 4°C. Cells 
were then washed three times and fixed in 1% paraformaldehyde. Flow 
cytometry was conducted on the Stratedigm-13 from Stratedigm Inc. (San Jose, 
CA, USA). All flow cytometric data were analyzed using FlowJo software (v10; 
FlowJo, LLC). 
 
Figure 4: Malignant cells negatively selected by magnetic bead sorting 
based on the patient’s malignant phenotype 
 
Cell Lines 
MyLa 2059,73 Sez4,74 HH,75 and Hut7876 are well established CTCL cell 
lines. MyLa 2059 and HH were cultured in RPMI 1640 medium supplemented 
with 10% heat-inactivated FBS, glutamine (2mM), penicillin 100μ/mL, and 
streptomycin (100μg/mL) at 37°C, 5% CO2, and 95% humidity. Sez4 was 
cultured in RPMI 1640 medium supplemented with 10% heat-inactivated FBS, 
glutamine (2mM), penicillin 100μ/mL, and streptomycin (100μg/mL), as well as 
IL2 (20ng/mL; R&D Systems) at 37°C, 5% CO2, and 95% humidity. Hut78 was 




glutamine (2mM), penicillin 100μ/mL, and streptomycin (100μg/mL) at 37°C, 5% 
CO2, and 95% humidity. All media and supplements were obtained from 
Invitrogen (Carlsbad, CA, USA). 
 
Statistical analysis 
For the Cell Viability Assay and Caspase-3/7 assays, each drug 
concentration was performed in quadruplicate, and the mean values were plotted 
with their respective standard deviation. The mean inhibitor concentration was 
determined using GraphPad Prism (Version 7.01). Patient samples were grouped 
using hierarchical clustering with Ward’s method77 in R (Version 3.0.1). 
Combination index (CI) values and standard errors were calculated using the 
Chou-Talalay method78 in Microsoft Excel. 
 
Quantitative Real-Time Reverse-Transcriptase-PCR 
RNA was extracted using the All-Prep DNA/RNA Micro Kit for patient 
samples, or with the All-Prep DNA/RNA Mini Kit for cell lines from Qiagen 
(Hilden, Germany) as per the manufacturer’s specifications. RNA was quantified 
using the BioTek Epoch spectrophotometer. 2μg of RNA was converted to cDNA 
using the High Capacity Reverse Transcription Kit from Applied Biosystems 
(Foster City, CA, USA) per the manufacturer’s instructions. Patient cDNA 
samples were then pre-amplified using the Applied Biosystems TaqMan® Pre-
Amplification Master Mix as per the manufacturer’s instructions. Gene expression 




and the Applied Biosystems 7500 Real Time PCR System. Samples were 
characterized in duplicates. Obtained Ct values were normalized to HPRT1 
expression and expression differences relative to healthy controls were 







CTCL patient population and peripheral blood analysis 
 To begin to assess the potential of the BCL2 inhibitor venetoclax in the 
treatment of CTCL with blood involvement (B1 or B2), peripheral blood samples 
were obtained from 25 patients diagnosed with CTCL who have a malignant cell 
population measured by flow cytometry. Patients were classified by their initial 
diagnosis as erythrodermic/Sézary syndrome (13/25), mycosis fungoides (10/25), 
or folliculotropic MF (2/25) (Table 1). Patient treatment statuses ranged from 
extracorporeal photopheresis (ECP) with or without adjunct therapies (18/25), to 
multimodal therapies (6/25), to cytoreductive therapy (1/25). Each patient 
sampled underwent clinical flow cytometry, from which blood parameters were 
calculated (Table 2). Patients were additionally tested for clonality by either PCR 
based T-cell receptor (TCR) gene rearrangement studies or the presence of a 
clonal Vβ antigen detectable by flow cytometry, with 25/25 patient samples 
positive for clonality based on one or both tests. Eight patients were classified as 
B1, and the remainder were classified as B2 based on the 2007 ISCL 






Table 1. Summary of CTCL patients’ peripheral blood flow cytometric 
parameters. Abnormal cell phenotype identified by flow cytometry as 
phenotypically atypical: TCR-Vβ positive if >50% of the population of atypical 
cells express a single Vβ, or by indirect evidence, if there is less than 20% 
expression of the entire 27 Vβ antibody panel.18 PCR positive if ≥1 of 3 PCR 
reactions identifies a clone. B-stage based on ISCL classification14 and the 2016 
criteria proposed by Gibson et al.18 Patients staged as B2 have elevated absolute 
CD3+ or CD3+ CD4+ cell counts, with the upper limits of normal defined as 
greater than 2245 cells/μl and greater than 1612 cells/ μl, respectively. 
CD4+CD7- and CD4+ CD26- percent specifications are defined as percent of 

















1 CD3+ CD4+ CD7- CD26-  Yes 20 Yes 8.37 19.7 14.1 B1 
2 CD3+ CD4+ CD26- Yes 2 Yes 179.0 8.6 80.2 B2 
3 CD3+ CD4+ CD26- Yes 12 Yes 2.12 8.9 34.3 B2 
4 CD3+ CD4+ CD7- CD26- Yes Indirect No 8.11 14.3 38.5 B2 
5 CD3+ CD4+ CD26-  Yes 16 Yes 15.6 10 71.5 B2 
6 CD3+ CD4+ CD7- CD26- Yes 1 Yes 28.69 86.2 84.5 B2 
7 CD3+ CD4+ CD7- CD26- Yes 13.6 None 56.81 83.9 58.7 B2 
8 CD3+ CD4+ CD7- CD26- Yes 12 Yes 24.78 54.9 71.4 B2 
9 CD3+ CD4+ CD7- CD26- N/A N/A Yes 10.22 38.9 36.5 B2 
10 CD3+ CD4+ CD7- CD26- Yes 13.1 Yes 7.06 44.3 25.5 B2 
11 CD3+ CD4+ CD26-  Yes 13.6 Yes 9.66 11.4 46 B2 
12 CD3+ CD4+ CD26- Yes Indirect Yes 5.18 1.9 48.5 B2 
13 CD3+ CD4+ CD7- CD26- Yes 21.3 Yes 59.63 89.8 88.7 B2 
14 CD3+ CD4+ CD26- No None Yes 4.45 16.2 4.8 B1 
15 CD3+ CD4+ CD7- CD26-  Yes Indirect Yes 6.95 63.9 62.6 B2 
16 CD3+ CD4+ CD7- CD26-  Yes Indirect Yes 20.02 87.2 76.3 B2 
17 CD3+ CD4+ CD7- CD26- Yes 7.2 Yes 4.7 30.4 33.8 B2 
18 CD3+ CD4+ CD7- CD26- Yes 7.2 Yes 3.74 27.4 26.0 B1 
19 CD3+ CD4+ CD7- CD26-  No None No 1.21 20.6 22.5 B1 
20 CD3+ CD4+ CD7- CD26- Suspicion Indirect Yes 1.63 22.5 24.5 B1 
21 CD3+ CD4+ CD7- CD26- Suspicion  5.3 None 4.75 69.6 71.8 B2 
22 CD3+ CD4+ CD7- CD26- Suspicion 17 Yes 1.75 19.9 18.5 B1 
23 CD3+ CD4+ CD26-  Yes 2 Yes 27.91 51.1 89.5 B2 
24 CD3+ CD4+ CD7- CD26- Suspicion Indirect Yes 1.3 23.7 23.8 B1 







Table 2. Summary of patient characteristics.  
Pt ID Sex Age CTCL Subtype Current Therapy Previous Therapy  
1 M 73 FMF ECP None 
2 M 84 SS Brentuximab, vorinostat 
PUVA, ECP, vorinostat, MTX, 
bexarotene, IFNα -2b, romidepsin, 
gemcitabine/doxorubicin, 
alemtuzumab,  
3 M 66 SS ECP NB-UVB, topical steroids 
4 M 85 SS ECP Topical steroids 
5 F 71 SS Gemcitabine 
ECP, bexarotene, topical steroids, 
IFNα-2b, vorinostat, romidepsin, 
belinostat 
6 M 73 SS Pralatrexate 
Romidpesin, ECP, bexarotene, 
topical steroids  
7 F 61 SS ECP, bexarotene Topical steroids, phototherapy 
8 M 77 SS Romidepsin, vorinostat ECP, NB-UVB 
9 M 70 SS Pralatrexate  
Romidepsin, vorinostat, 
mechlorethamine, ECP 
10 M 71 MF ECP, bexarotene  NB-UVB, topical steroids 
11 F 79 SS 
ECP, bexarotene, 
vorinostat, INFα-2b  
Topical steroids 
12 F 64 SS ECP, bexarotene  Topical steroids 
13 F 76 SS ECP None 
14 M 61 MF ECP, NB-UVB None 
15 M 67 SS ECP, bexarotene  None 
16 F 40 FMF ECP, bexarotene  NB-UVB, TSEBT 
17 M 66 SS 
ECP, bexarotene, NB-
UVB, topical steroids 
None 




19 M 87 MF ECP MTX, bexarotene, topical steroids 




21 M 70 MF (V) EPOCH None 
22 M 77 MF ECP, bexarotene  NB-UVB, topical steroids 
23 M 52 MF Gemcitabine 
NB-UVB, bexarotene, vorinostat, 
ECP, IFNα-2b, Romidepsin,  
 




25 M 62  MF ECP, bexarotene Topical steroids 
 
Abbreviations: ECP, extracorporeal photopheresis; EPOCH, etoposide, prednisone, 
vincristine, cyclophosphamide, doxorrubicine; F, female; FMF, folliculotropic mycosis fungoides; 
IFN, interferon; M, male; MF, mycosis fungoides; MTX, methotrexate; NB-UVB, narrow band 
ultraviolet-B; PUVA, psoralen ultraviolet light A; SS, Sézary syndrome; TSEBT, total body 




CTCL patient samples show highly variable sensitivity to venetoclax in vitro 
 We observed the cytotoxic/cytostatic effects of venetoclax in all 25 CTCL 
patient samples after 72 hours of incubation as measured by the change in cell 
viability via media ATP quantitation. Patient samples demonstrated a wide range 
of sensitivities to venetoclax, with mean 50% inhibitory concentrations (IC50) 
ranging from picomolar (85 pM) to micromolar (6.6 µM) levels. The observed 
heterogeneity in sensitivity to venetoclax is not dissimilar to the variation 
observed in T-ALL79 or CLL.59 The most sensitive samples compare favorably to 
pre-clinical studies in B-cell lymphomas, the results of which have since been 
validated via clinical trial.60. In order to better study the significance and origins of 
the observed variation, we used hierarchical clustering based on their 
responsiveness to venetoclax to divide the tested samples into two groups, low 
and high responders. The majority of tested samples (20/25) were defined as 
high responders with a group mean IC50 of 79.0 nM compared to the low 
responders (5/25) with a group mean IC50 of 3.2 µM. Dose response curves for 
three representative samples: the most sensitive, the median, and the most 
resistant sample, are shown in Figure 5Bi.  
 Four established CTCL cell lines—MyLa 2059, Sez4, HH, and Hut78—
were also analyzed for sensitivity to venetoclax (Figure 5Bii). All four cell lines 
demonstrated relatively low sensitivity to venetoclax with IC50s of 2.47 µM, 7.4 
µM 10.2µM, and 33.6 µM respectively. In addition to the differences in IC50, cells 
lines and patients were observed to have different patterns in their dose 




to patient samples (P<.0001) suggesting distinct mechanisms of action between 
cell lines and patients (Figure 5C). Among patient samples, there was a 
statistical trend noted between response status and Hill slope (P=.07; data not 
shown). Hypothesizing an association between tumor burden and increased 
sensitivity to induction of apoptosis via inhibition of BCL2, we compared the 
mean inhibitory concentration of venetoclax between patients classified as B1 
versus B2 (ISCL Classification)14, as well as between patients classified as 
mycosis fungoides (non-erythrodermic) versus Sézary syndrome (erythrodermic), 
and found a higher sensitivity in patients with more advanced disease, and in 






Figure 5. Cell line and patient samples demonstrate variable sensitivity to 
venetoclax. Isolated malignant cells from patient samples and 4 human-derived 
CTCL cell lines were incubated with a range of concentrations of venetoclax for 
72 hours from which IC50s and Hill slopes were calculated. The median and 
mean IC50 for patient samples were 102nM and 833nM, respectively. (A) Patient 




responders using hierarchical cluster analysis. (B) Representative dose response 
curves for patient samples (Bi), and CTCL cell lines (Bii). (C) Comparison of Hill 
slopes between patient samples and cell lines. The difference between them 
would suggest distinct methods of actions. (D) Patient samples are most likely to 
be sensitive to venetoclax in more advanced disease. Stage based on ISCL 
classification.14 (E) Patient samples classified as Sézary syndrome (SS) are 
more likely than mycosis fungoides (MF) patients to be sensitive to venetoclax.  
 
Baseline BCL2 mRNA expression predicts in vitro sensitivity to venetoclax 
To study the differences in response to venetoclax among both primary 
patient samples and cell lines, the baseline genetic expression of four BCL2 
family members was measured using quantitative RT-PCR and expressed 
relative to the mean expression of the healthy controls (Figure 7A). Significant 
differences were noted in BCL2 expression between high and low responders as 
well as high responders and cell lines, while none were observed between low 
responders and cell lines. Patient samples expressed lowers amounts of BCL2 
than healthy controls, on average 29% less but this difference was not 
statistically significant (P=.19). Also notable was the similar expression of 
BCL2L1 (the gene encoding BCL-XL) among patient samples and cell lines, with 
both sets demonstrating no difference relative to the healthy controls. Significant 
differences were noted in the expression of BCL2L11 (the gene encoding BIM) 
among cell lines, with high expression noted in Hut78, and low or undetectable 
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Figure 6. Baseline Gene Expression.  (A) Baseline BCL2L11 expression in the 
four tested CTCL cell lines, MyLa, HH, and Hut78, measured as a fraction of 
healthy controls. BCL2L11 expression was not detected in the HH cell line after 
40 cycles of RT-PCR. (B) Baseline expression of BCL2L1, BCL2L11, MCL1 and 
BAX in primary patient samples did not correlate to sensitivity to venetoclax. 
 
 For the 20 patient samples examined, IC50 values were plotted as a 
function of relative expression of BCL2 member mRNA. While a negative 




(Spearman r= -0.52, P= .018) (Figure 7B), mRNA expression of other BCL2 
family members (BCL2L1, MCL1, BCL2L11, BAX) did not correlate with the IC50 
values (Figure 6B). Furthermore, we examined ratios of expression of BCL2 to 
the other tested BCL2 family members and found that higher ratios of BCL2 to 
BCL2L1 correlate with greater sensitivity to venetoclax in vitro, while ratios of 
BCL2 to MCL1 and BCL2 to BCL2L11 do not (Figure 7C). These results point to 
the importance of both BCL2 and BCL2L1 expression, and indeed relative 
expression of one another, to the survival of malignant T-cells. Additionally, the 
limited correlations of both BCL2 and the BCL2/BCL2L1 ratio to sensitivity 
suggest that a more complex relationship between BCL2 expression and 
inhibition of apoptosis may exist.  
 
Figure 7. Baseline gene expression of BCL2 family members and 
correlation to IC50. BCL2, BCL2L1, MCL1, and BCL2L11 were measured in 20 




fraction of the mean of the healthy controls. (A) Baseline expression of BCL2 was 
found to differ significantly between high responders and low responders. No 
difference was found between low responders and cell lines. BCL2L1 was 
expressed similarly among all four groups. Decreased MCL1 expression was 
noted in cell lines compared to patient samples. (B) BCL2 mRNA expression may 
predict response to venetoclax in vitro, with higher expression correlating to 
increased sensitivity. (C) Increased ratios of expression of BCL2 to BCL2L1 
predicts higher sensitivity to venetoclax.  
 
Combination inhibition of BCL2 and histone deacytelase results in synergistic 
killing of CTCL cells from patient samples 
 Fifteen of the CTCL patient samples were tested for synergy between 
venetoclax and two HDAC inhibitors, vorinostat and romidepsin. Each of the 
three drugs was tested individually and in combination and IC50 values and Hill 
slopes were calculated. From these dose response curves, the combination 
index (CI) was calculated using the Chou-Talalay method in Microsoft Excel, with 
a CI<1 indicating a synergistic interaction80. For combinations of venetoclax with 






Figure 8. Combinations of venetoclax with either romidepsin or vorinostat 
demonstrate synergy in patient derived cultures. (A) Viability curves for 
venetoclax, vorinostat and their combination for Patient 11. After 72 hours of 
incubation the viability curves and the combination index were calculated using 




shown with standard deviations. (B) Viability curves for venetoclax, romidepsin 
and their combination for Patient 11. (C) CI and fitted curves for the combination 
of venetoclax and vorinostat for Patient 11. (D) CI and fitted curves for the 
combination of venetoclax and romidepsin for Patient 11. (E) Caspase-3/7 
activation after 24 hours of incubation of the cell culture derived from Patient 11 
with venetoclax, vorinostat, romidepsin and their combinations. All concentrations 
were studied in quadruplicate and plotted are the means with their respective 
standard deviations. (F) A significant increase in activation of caspase is seen in 
higher concentration combinations. Effects are similar for combinations of 
venetoclax with either vorinostat (Fi), and romidepsin (Fii).  
 
93% of tested samples demonstrated synergy of response with combinations of 
venetoclax and vorinostat at 10% viability (0.9 fraction affected), while 73% 
demonstrated synergy of response between venetoclax and romidepsin (Figure 
8C,D; Figure 9A; Table 3). No correlation was found between either expression 
of BCL2 or sensitivity to venetoclax and the degree of synergy (data not shown). 
Additionally, no differences were found between mycosis fungoides patients or 
Sézary syndrome patients and degree of synergy, for combinations of venetoclax 






 Figure 9. Summary of Combination Index data. For each of the 15 patient 
samples tested for synergy between venetoclax and either vorinostat or 
romidepsin the combination index was calculated at 10% viability (0.9 fraction 
affected). No correlation was found between the combination index and the 
diagnosis at original presentation. Each patient was classified as either Sezaré 
Syndrome (erythrodermic) or mycosis fungoides (non-erythrodermic). 
 
 In order to investigate the mechanism of action, the induction of apoptosis 
at 24 hours was measured by caspase 3/7 activation. Dose response curves 
were again produced for venetoclax, vorinostat, and romidepsin individually and 
in combination. The effect of combination therapy upon caspase 3/7 activity 
displayed a dose-dependent action (Figure 8E). Our measurements of caspase 
activation support the observations made with the cell viability assay regarding 
the form of interaction between venetoclax and the HDAC inhibitors, in which 
there are disparate effects at low and high drug concentrations. At low doses of 
venetoclax and either HDAC inhibitor, antagonism was observed. In contrast, we 
observed a significant increase in caspase 3/7 activity with combination therapy 






Table 3: Calculated combination index at 10% viability (0.9 fraction affected) for 
each tested patient sample.  Synergistic interactions are noted in green, while 
antagonistic interactions are noted in red, as per the legend (Adapted from 
Chou78). 93% of samples displayed synergy between venetoclax and vorinostat. 




Drug IC50 [nM] Combination Index at 10% Viability (± SEM) 
Pt # Venetoclax Vorinostat Romidepsin Venetoclax + Vorinostat Venetoclax + Romidepsin 
2 6.467 2569 2.310 0.75 ± 0.09  0.50 ± 0.05 
3 9.607 1254 1.515 0.05 ± 0.24 0.24 ± 0.06 
4 12.11 57.17 7.927 0.13 ± 0.05 0.90 ± 4.10 
5 15.06 1813 6.759 0.63 ± 0.09 1.34 ± 0.20 
6 15.98  2032 15.15 0.39 ± 0.06 0.62 ± 0.07 
7 18.95 2202 2.066 1.75 ± 0.16 1.43 ± 0.29 
8 22.86 1531 1.245 0.52 ± 0.07 0.78 ± 0.20 
10 51.25 1468 1.764 0.92 ± 0.38 0.90 ± 0.27 
11 67.19 4761 4.163 0.32 ± 0.03 0.30 ± 0.03 
12 99.1 1486 8.556 0.59 ± 0.14 1.07 ± 6.28 
13 102 2260 2.138 0.44 ± 0.10 0.58 ± 0.21 
14 115.1 465.7 1.867 0.84 ± 0.22 0.40 ± 0.08 
15 128.9 1266 3.884 0.57 ± 0.46 3.45 ± 29.51 
21 1040 2160 1.357 0.67 ± 0.24 0.42 ± 0.10 
23 2891 5387 2.577 0.65 ± 0.21 0.62 ± 0.49 
   
% Synergistic 93 73 
 
 
 Synergy studies were similarly performed on the cell lines (Figure 10). The 
only cell line to display significant synergy was MyLa 2059 when venetoclax was 




vorinostat had antagonistic responses. In combinations of venetoclax and 
romidepsin, only the HH cell line demonstrated synergistic sensitivity. Unlike the 
response of patient cells which are well modelled by the Hill and median-effect 
equations, the cell lines display significant deviations from the expected 
responses, especially at high doses. This may be attributed to the heterogeneity 
of the cell lines, which are not necessarily clonal, or to the highly cytotoxic effects 
of drugs such as romidepsin at higher doses.26,81 Thus, our ability to detect 
synergy at these dose ranges is limited.  
 
Figure 10. Searching for synergy in CTCL cell lines. Four CTCL cell lines 
were tested for synergy between venetoclax and vorinostat, and between 
venetoclax and romidepsin. Cell lines were first incubated with incremental 




lines were incubated with combinations of each drug in an approximate 1:1 ratio 
of the calculated IC50 values. Synergy was noted between venetoclax and 
vorinostat in the MyLa cell line and between venetoclax and with high doses of 
romidepsin in the HH cell line.  
 
BCL2 family member expression changes in response to HDAC inhibition 
 To provide insight into the mechanism of action of synergy and 
antagonism between venetoclax and the HDAC inhibitors romidepsin and 
vorinostat, we incubated the four CTCL cell lines for 24 hours with 5μM vorinostat 
or 5nM of romidepsin before isolation of RNA and measured the relative 
expression of 7 BCL2 family members compared to a DMSO vehicle control via 
qRT-PCR (Figure 11A). Following exposure to vorinostat there was a 40-fold 
increase in BCL2L11 expression and a 12-fold increase in BMF expression. The 
dramatic increase in BCL2L11 mRNA is critical to the function of BCL2, which 
acts to inhibit apoptosis via direct binding to BIM. This shift in balance towards 
pro-apoptotic factors is not only one of the methods of action of vorinostat, but 
sheds light on interactions between venetoclax and HDAC inhibition. 
Furthermore, we were able to detect a statistically significant trend between the 
change in expression of BCL2 in response to vorinostat and the calculated 
combination index at a fraction affected of 0.9 (Figure 11B). MyLa, the only cell 
line in which BCL2 expression was increased, was the only cell line to 
demonstrate significant synergy. Romidepsin caused a 13-fold increase in BMF 
and 4-fold increase in BCL2L11 expression. No significant changes in expression 





 Figure 11. Changes in genetic expression of BCL2 family members 
following incubation with vorinostat or romidepsin. (A) Significant changes 
include the increased expression of BCL2L11, BMF, and MCL1. Notable is the 
2.7-fold increase in BCL2 expression in the MyLa cell line with vorinostat. (B) The 
amount of calculated synergy, represented by the combination index at 0.9 
fraction affected (10% viability) was correlated to change in expression of BCL2 
after 24 hours of incubation with 5µM vorinostat, a strong correlation was noted, 







Guided by recent studies5,27,82–85 that suggest that increased resistance to 
apoptosis in CTCL is at least partly due to gene alterations that may increase the 
transcription of BCL2, and encouraged by the success of venetoclax in the 
treatment of CLL,86 we sought in this study to explore the potential of venetoclax 
for the treatment of CTCL. We identified a group of patients, the high responders, 
with exquisite sensitivity to venetoclax at a mean IC50 of 79.0 nM. This range is 
comparable to the range of sensitivities, <300 nM previously observed in BCL2 
dependent immature CD4- CD8- T-ALL subtypes. Three clinical trials87–89 
investigating the treatment of CLL and NHL found the maximum plasma 
concentrations for 400mg, 800mg, and 1200mg to be 2.2µM, 3.5µM and 4.0µM. 
These values far exceeded the in vitro mean inhibitory concentrations observed 
in our study. We are further encouraged as the maximum tolerated dose of 
venetoclax has not yet been well established, necessitating dose escalation 
beyond 1200mg.90,91 Indeed, the most significant adverse events in the trials for 
CLL were deaths due to tumor lysis syndrome.92  
 Having established the response of primary patient samples to venetoclax 
in vitro, we next searched for a biological assay that would predict sensitivity and 
distinguish high responders from low responders. BCL2 protein and mRNA 
expression have been found to have an inverse relationship with sensitivity to 
venetoclax in vitro CLL,93 NHL,59 and T-ALL.79 Our data indicates that a similar 
relationship exists in CTCL, additionally supported by the significant difference in 




expression of BCL2L1 and MCL1 contribute to resistance to venetoclax,60,70,72,94 
but our work suggests that higher expression of either at baseline does not 
correlate with sensitivity in the patient samples tested.  
Previous work79,95,96 with T-ALL has identified a wide variation in response 
to venetoclax among cell lines and primary patient samples, wherein T-ALL cells 
displaying the immature phenotypes CD4- CD8-, such as LOUCY cell line, 
exhibit BCL2 dependence, and correspondingly submicromolar sensitivity in vitro 
to venetoclax. In contrast, cell lines with mature phenotypes demonstrate 
dependency for survival on the protein BCL-XL, and decreased sensitivity to 
venetoclax with greater than 1μM IC50 values. CTCL itself has been 
characterized by TCR sequencing97 as a disease derivative of mature memory T-
cells, from which one would predict dependency on BCL-XL. Direct 
measurements of mitochondrial membrane depolarization98,99 have highlighted 
the stark differences in responses to BH3 mimetics between BCL2 and BCL-XL 
survival-dependent cells. A recent study100 looked at the BH3 profiles of T-cell 
lymphomas cell lines, including two examined in our study, MyLa and Hut78. The 
two cell lines were identified as BCL-XL dependent, which was confirmed in our 
study, as we measured similar expression of BCL2L1 in all three cells as well as 
significantly decreased expression of BCL2 and MCL1, relative to normal 
controls. These findings, along with our observation of poor sensitivity of the 
three cell lines to the BCL2 selective inhibitor venetoclax, suggest that some 
CTCL cases are BCL-XL dependent. This interplay of BCL2 and BCL-XL was 




had a higher expression of BCL2 than BCL2L1, and a larger ratio predicted of 
sensitivity to venetoclax.  
Synergy has been described between BCL2 inhibitors with a number of 
different therapies and in numerous malignancies.62,63,79,95,101–104 Here, we show 
evidence of synergy between venetoclax and two HDAC inhibitors vorinostat and 
romidepsin. Synergy was consistently observed at the higher dose ranges of 
either HDAC inhibitor indicating a dose-dependent mechanism. Not only did we 
detect antagonism at low doses, but there was some evidence of direct inhibition 
of caspase 3/7 activity with administration of either HDAC inhibitor alone. This is 
consistent with reports on both romidepsin66 and vorinostat105 which showed the 
effects of either drug differ dramatically at low and high dose, including one study 
where romidepsin was found to inhibit the production of reactive oxygen species 
at low doses.68  
The lack of synergy observed in the CTCL cell lines suggests, perhaps 
unsurprisingly, that expression of and dependence on BCL2 is required for 
synergistic interactions with other therapies. While in the cell lines the observed 
synergy can be linked directly to changes in BCL2 expression, the preferential 
effect observed with vorinostat and venetoclax is likely due to the greater degree 
of change in the expression of BCL2L11. Dissociation of BCL2-BIM complexes 
have been implicated as the primary mechanism of induction of apoptosis by 
venetoclax and other BCL2 inhibitors.21, 46, 68 The low baseline expression of 




change in expression of BCL2L11 is critical to apoptosis by romidepsin, while 
baseline expression is non-essential to therapeutic effects.107,108  
In summary, this study supports the clinical implementation of venetoclax 
as a novel therapy for leukemic CTCL, and further demonstrates a synergistic 
effect when venetoclax is combined with the HDAC inhibitors romidepsin and 
vorinostat. The potential for an effective combination oral therapy with venetoclax 
and vorinostat is also intriguing. Further clinical trials are planned to explore this 
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Abstract 
MicroAbstract: Several studies have suggested that hematopoietic stem cell 
transplant (HSCT) may provide a cure for Primary Cutaneous Aggressive 
Epidermotropic Cytotoxic CD8 positive T-Cell Lymphoma (CD8+ PCAETL). We 
summarize published literature on this disease and present outcomes of 8 
patients with CD8+ PCAETL treated at our institution. In our experience, 
allogeneic HSCT and the novel agents brentuximab and pralatrexate 
demonstrate substantial activity against this disease.  
 
Structured Abstract: 
Background: Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8 
positive T-Cell Lymphoma (CD8+ PCAETL) is a rare subtype of peripheral T-cell 
lymphoma with poor outcomes and without a standardized treatment strategy. 
Allogeneic hematopoietic stem cell transplantation (HSCT) has been suggested 




Methods: We conducted a retrospective case series. We identified eight patients 
with the diagnosis of CD8+ PCAETL, four of whom also underwent allogeneic 
HSCT.  
Results: Eight patients were treated at our center with combination 
chemotherapy and several novel agents, including HDAC inhibitors, 
Brentuximab, and Pralatrexate. Patients underwent a median of 8.5 treatments 
prior to HSCT. Six of the eight patients examined, including all four who received 
a HSCT, were alive at their last follow up.  
Conclusion: Allogeneic HSCT is a promising treatment modality for CD8+ 
PCAETL. Given the aggressive nature of this disease and lack of sustained 
remission with currently available therapies, HSCT should be considered early in 
the course of treatment. Two novel agents, brentuximab and pralatrexate, 
demonstrated significant activity against CD8+ PCAETL, and may be 






Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8 positive T-
Cell Lymphoma (CD8+ PCAETL) comprises 1% of all cases of cutaneous T cell 
lymphomas. The disease was given provisional status under the umbrella 
category Peripheral T-Cell Lymphoma Not Otherwise Specified (PTCL-NOS), in 
the 2005109, 2008110, and 2016111 WHO-EORTC classifications. The disease 
remains a diagnostic challenge as subtypes may lack markers such as CD8 and 
the αβ-TCR112–114 originally thought to be essential to the diagnosis, and due to 
histopathologic mimickers of the disease such as lymphomatoid papulosis Type 
D115. PCAETL is characterized by disseminated ulcerative lesions, frequent 
extra-cutaneous involvement, and a high mortality rate. There exists no 
standardized treatment algorithm and treatment strategies vary widely among 
centers. Several studies and case reports have suggested that hematopoietic 
                                                          
Abbreviations: AE, adverse effects; AML, acute myeloid leukemia; ATG, anti-thymocyte globulin; 
AWD, alive with disease; AWOD, alive without disease; BEAM, carmustine, cytarabine, 
etoposide, melphalan; BMT, bone marrow transplant; BTX, bexarotene; Bu, busulfan; CD8+ 
PCAETL, Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8 positive T-Cell 
Lymphoma; CHASE, cylophosphamide, cytosine arabinoside, etoposide, and dexamethasone; 
CHOEP, cylophosphamide, adriamycin, vincristine, etoposide, prednisone; CHOP, 
cylophosphamide, adriamycin, vincristine, prednisone; CR, complete response; D, dead; 
DICE, dexamethasone, ifosfamide, cisplatin, etoposide; DHAP, dexamethasone, cytarabine, 
cisplatin; DLI, donor lymphocyte infusion; DOL, death of lymphoma; ECP, extracorporeal 
photopheresis; EORTC, European Organisation for Research and Treatment of Cancer; EPOCH, 
etoposide, prednisone, vincristine, cyclophosphamide, doxorrubicine; F, female; Flu, fludarabine; 
Gem, gemcitabine; GVHD, graft versus host disease; HDAC, histone deacetylase; HSCT Hyper-
CVAD, cyclophosphamide, vincristine, doxorubicine hydrochloride, dexamethasone; ICE, 
ifosfamide, carboplatin and etoposide; M, male; MCEC, ranimustine, carboplatin, etoposide, 
cyclophosphamide; MIDLE, methotrexate, etoposide, ifosfamide, mesna, l-asparaginase; MTX, 
methotrexate; mo, months; N/A, not applicable; ND: Not Documented; NM, nitrogen mustard NR: 
No Response; PD, progressive disease; PPX, prophylaxis; PR, partial respone; ProMACE-
CytaBOM, cyclophosphamide, doxorubicin, etoposide cytozar, bleomycin, vincristine, 
methotrexate and prednisone; PTX, pralatrexate; PUVA, psoralen ultraviolet light A; Romi, 
romidepsin; SCT, stem cell transplant; SMILE, dexamethasone, methotrexate, ifosfamide, L-
asparaginase, etoposide; TBI, total body irradiation TSEBT, Total skin electron beam therapy; 





stem cell transplant may represent a definitive, and potentially curative 
therapy112,116,117. In this review we present our single-center experience of eight 
cases of CD8+ PCAETL, including 4 who underwent allogeneic stem cell 
transplantation, and a review of 18 published cases describing the use of 
transplant in these patients.  
Methods 
We performed a retrospective analysis of all patients with the diagnosis of 
CD8+ PCAETL treated at the Yale-New Haven Hospital between 2007 and 2017. 
Patients were included in the analysis if they met the clinical, histopathologic, and 
molecular criteria for CD8+ PCAETL defined by the 2016 WHO classification, 
including an epidermotropic proliferation of abnormal cytotoxic CD8+ 
lymphocytes. Two patients were previously reported as a part of a larger case 
series112. Immunohistochemistry was obtained and included antibodies against 
the following: CD2, CD3, CD4, CD5, CD7, CD8, CD20, CD30, CD56, β-F1 TIA-1, 
and/or granzyme B. Demographic information, symptoms, treatment, outcome, 
and follow-up information were obtained and documented in Tables 1, 2, and 3. 
Yale University’s Institutional Review Board granted exempt status for this 
retrospective case series.  
We conducted a review of the literature to identify previously reported 
cases where bone marrow or stem cell transplants were used for the treatment of 
CD8+ PCAETL. A MEDLINE (Ovid), Embase (Ovid), and Web of Science search 
was performed using the search words “Primary Cutaneous Aggressive 




“Cutaneous T-Cell Lymphoma”, along with “bone marrow transplant”, “allogeneic 
stem cell transplant”, “autologous stem cell transplant”, and “stem cell 
transplant”. Additional cases were identified using citation searches. A total of 18 
cases were identified (Table 5).112,118–128 
 
Results 
Patient Characteristics  
 We identified eight cases with a diagnosis of CD8+ PCAETL. A complete 
list of patient characteristics can be found in Table 1. The median age at time of 
diagnosis was 53 years (range 20 to 77 years). The most common clinical skin 
presentation was with multiple ulcerated lesions, with one patient unique in only 
having a single lesion, and another with no ulceration. Lesions were either 
patch/plaque or tumors, with two patients presenting with both. PET scanning 
demonstrated FDG avid lymphadenopathy in 5 of 8 patients. One patient had 
lymph node involvement confirmed by biopsy. A single patient presented with 
visceral involvement, with diffuse metastasis, including the brain. Bone marrow 
involvement was done in 5 patients and none showed involvement. Three of 
eight patients had presence of circulating neoplastic cells on flow cytometry.  
Pathology 
Pathology was consistent among the 8 patients and included presence of 
epidermitropism and atypical lymphocytes with hyperchromatic nuclei. Invasion 
of hair follicles was noted in 2 of 8 patients, though hair follicles were not present 




with frank ulceration were seen in 4 of 8 samples. Infiltrates extended into the 
dermal papillae (3 of 8), superficial (5 of 8), mid (3 of 8), deep dermis (2 of 8), 
and superficial panniculus (1of 8). Red cell extravasation and mild vascular 
ectasia were seen in 3 of 8 biopsies. Both small/medium lymphocytes (4 of 8) 
and large lymphocytes (4 of 8) were noted. 
Immunophenotyping was performed on all samples (Table 3, 4). All 8 
samples were found to be CD3+, and the majority (7/8) were CD8+ as well. This 
includes one sample that was found to be positive for both CD4 and CD8. One 
patient was CD4- and CD8-, though otherwise pathologically identical to the 
other samples. Samples showed variable expression of CD2, CD5, and CD7. In 
all samples TIA-1 (7/7) and granzyme (2/2) were expressed. All samples that 
were tested were positive for the cytotoxic marker β-F1, and negative for γδ 
surface markers.  
Treatment and Outcome  
Treatment and outcomes for the 8 patients are summarized in Table 1 and 
3, and more detailed information can be found for each individual patient in Table 
4. Systemic chemotherapy was used in all but one patient. The only patient not to 
receive systemic therapy was the only patient without multiple, disseminated 
lesions. The tumor in this patient regressed following radiation therapy to the 
area. Other complete responses were achieved with total skin electron beam 
therapy (TSEBT) (1/4), allogeneic stem cell transplantation (SCT) (3/4), 
adriamycin, vincristine, prednisone (CHOP) chemotherapy (1/2), vincristine, 




gemcitabine based chemotherapy (1/5) and brentuximab therapy (1/4); however, 
durable responses were observed only with allogeneic SCT or brentuximab 
therapy. Of the 4 patients who were treated with brentuximab vedotin, 3 had 
CD30 staining in their tumor cells and the fourth was CD30 negative. Of the four 
patients who received an allogeneic SCT, two received a matched-related donor 
(MRD) transplant, one received an unrelated donor (URD) transplant, and one 
received a double unrelated umbilical cord blood transplant. One patient received 
two donor lymphocytes infusions. Conditioning among the four patients was 
either reduced intensity conditioning with fludarabine and buslfan (1/4), or 
standard myeloablative therapy with total body irradiation (1/4) with either 
pentostatin (1/4) or fludarabine and cyclophosphamide (1/4). Six patients remain 
alive, including all four who received a SCT. Four patients with active disease are 
on salvage chemotherapy and two are without evidence of disease. Of the two 
patients who died, one died as a result of complications from lymphoma with 
diffuse visceral involvement, and one due to sepsis. The median follow-up time 







Table 1: Patient Cohort Characteristics 
Variable n (%) 
Sex (female, male) 5, 3 
Median age, y (range) 53 (20-77) 
Presentation  
Single Lesion 1 (12.5%) 
Multiple Lesions 7 (87.5%) 
Patch/plaque 6 (75%) 
Tumor 4 (50%) 
Ulceration 7 (87.5%) 
Lymphadenopathy 5 (62.5%) 
Visceral Involvement  1 (12.5%) 
Bone marrow involvement 0 (5) (0%) 
Circulating tumor cells 3 (37.5%) 
B symptoms 0 (0%) 
LDH elevated 1 (12.5%) 
Therapies  
Median number of therapies 
(range) 
8.5 (1-13) 
Chemotherapy 7 (87.5%) 
CHOP 2 (25%) 
EPOCH 4 (50%) 
DICE 1 (12.5%) 
Hyper CVAD 1 (12.5%) 
DHAP 2 (25%) 
SMILE 1 (12.5% 
MIDLE 1 (12.5%) 
Gemcitabine 5 (62.5%) 
Pralatrexate 5 (62.5%) 
Bendasmutine 2 (25%) 
Vinorelbine 2 (25%) 
HDAC inhibitors 6 (75%) 
Brentuximab 4 (50%) 
UCHT1 1 (12.5%) 
Denileukin Diftitox 3 (37.5%) 
Alemtuzumab 1 (12.5%) 
Pembrolizumab 1 (12.5%) 
TSEBT 4 (50%) 
Radiation 2 (25%) 
Allogeneic Transplant 4 (50%) 
DLI 1 (12.5%) 
Status at Last Follow-up  
Alive without disease 2 (25%) 
Alive with disease 4 (50%) 
Dead of lymphoma or 
complications 
2 (25%) 
Median follow-up time, mo 
(range) 
40 (6-171) 











CD2 2 (7) 29 
CD3 8 (8) 100 
CD4 1 (6) 17 
CD5 4 (6) 67 
CD7 3 (6) 50 
CD8 7 (8) 88 
CD30 2 (6) 33 
TIA-1 7 (7) 100 
Granzyme B 2 (2) 100 
γδ-TCR 0 (6) 0 
β-F1 6 (6) 100 
 
Table 3: Summary of Treatment Response 
Treatment Number of patients with Documented 
Response, either SD, PR, or CR (n) 
% 
Response 
EPOCH 3 (4) 75% 
Gemcitabine 4 (5) 80% 
Pralatrexate 3 (5) 60% 
HDAC Inhibitors 0 (6) 0% 
Brentuximab 4 (4) 100% 
TSEBT 3 (4) 75% 





Table 4: Individual patient immunophenotype, treatment, outcome, current status 
Pt Age at 
diagnosis, y 
Immunophenotype Treatment and Response BMT Conditioning Current 
Status 
1 36 Positive: CD3, CD4, CD8, 
CD30, TIA-1, Granzyme-B  
Negative: ND 
CHOP (PR), bexarotene (PR), Vorinostat (PD), TSEBT (PR),  
Denileukin Diftitox (PR), gem/vinorelbine/doxorubicin (PR, d/c due to 
AE), EPOCH (PD), Romidepsin (PD), PTX (PD), 
Brentuximab/cyclophosphamid/adriamycin/ 
prednisone (PR), HSCT (CR)  
Allogeneic Flu/BU AWD 
2 77 Positive: CD3, CD8, TIA-1, 
β-F1 
Negative: CD2, CD4, CD5, 
CD7, CD20, CD30, CD56 
XRT (CR)   AWD 
3 52 Positive: CD3, CD5, CD8 , 
TIA-1, β-F1 
Negative: CD2, CD4, CD7, 
CD30 
PTX (PR), XRT (PR), gem/doxorubicin (PR), TSEBT(PD), romidepsin 
(PD), ICE (PD), CHOP (CR), HSCT (relapse), bendamustine and 
brentuximab (SD) 
Allogeneic TBI AWD 
4 54 Positive: CD3, CD8 
Negative: CD2, CD5 
TSEBT (PR), ECP (PD), Hyper-CVAD (PD), DICE (PD), XRT (PD)   DOL 
5 61 Positive: CD2, CD3, CD5, 
CD7, CD45RO, CD56, TIA-
1 
Negative: CD4, CD8 
TSEBT (PR), PTX (PD), EPOCH (PR)   AWD 
6 50 Positive: CD2, CD3, CD8, 
TIA-1, β-F1 
Negative: CD4, CD7, CD30 
Vorinostat (PD), romidepsin (PD),  
denileukin diftitox/bexarotene (PR), gem (PD), 
alemtuzumab (PD), brentuximab (PR, d/c due to AE), peg-
interferon/mechlorethamine (PD), PTX (PR), pembrolizumab (PD)  
  D, sepsis 
7 20 Positive: CD3, CD5, CD7, 
CD8, TIA-1, β-F1  
Negative: CD2, CD4, CD30 
PTX (PR), romidepsin (PD), gem (PD), UCHT1 (PD), EPOCH (PR), 
bendasmutine (PD), DHAP (SD), TSEBT (CR), MIDLE (PR), 




8 65 Positive: CD3, CD5, CD7, 
CD8, CD30, TIA-1, 
Granzyme B,  
Negative: CD2, CD4 
EPOCH (CR), romidepsin (PD), cyclophosphamide (PD), 
gem/oxaliplatin (CR), HSCT (relapse), EPOCH (PD), DHAP (PD), 








Table 5: Summary of cases from literature 
 




Sex Sx if specified Immunophenotype Previous 
Treatment 
Conditioning RR Response 
duration, 
months  












Positive: CD3, CD5, CD7, 
CD8, Ia 
Negative: CD2, CD4, CD25, 
CD30, T9  
Interferon alfa 2b, 
topical NM, MTX  
ND CR, 
relapse 
ND ND Relapsed, treated with 
PUVA, alive with stable 
disease 36mo after 
diagnosis 





Positive: CD3, CD5, CD7, 
CD8, Negative: CD2, CD4, 

















Positive: CD3, CD7, CD8, 
CD45RA, TIA-1, TCR-β 
Negative: CD1a, CD2, CD4, 
CD5, CD25, CD30, CD45RO, 
Granzyme B, Perforin 
Interferon alfa , 
ProMACE-
CytaBOM 
ND NR 0 ND Following BMT treated 
with TSEBT without 
response. Succumbed 




 1 Allogeneic  44 F Generalized 
ulcerative lesions 
Positive: CD3, CD7, CD8, 
CD25, TIA1, perforin, TCR-β 




CR 17 mo Tacrolimus, 
MTX 
GVHD with total-body 
desquamation, resolved 









Positive: CD8, CD45A, β-F1  




XRT, TSEBT, gem  
flu/ melphalan, 
alentuzumab 











6 F Disseminated 




Positive: CD2, CD3, CD5 
(very weak), CD8, CD45RO 
(very weak), TIA, granzyme B 
Negative: CD4, CD7, CD20, 











NR 0 ND Lesion remained 
followed transplant, 
treated with TSEBT, 










































1 BMT 31 M Ulcerated 
patches, plaques, 
nodules 
Positive: CD7, CD8, CD45RA, 
MIB-1, β-F1 













1 Autologous  57 M Ulcerated 
plauqes and 
tumors 
Positive: CD3, CD8, CD7, 
CD56, β-F1 
Negative: CD4, CD30 
Systemic 
chemotherapy 





6 Allogeneic  19 F Plaque, platch Positive: CD3, CD5, CD7, 
CD8, CD45RA, TIA-1, 
Granzyme B, β-F1 
Negative: CD2, CD4, CD30, 
CD56 






46 mo ND AWOD 
Allogeneic  28 M Psoriasiform 
dermatitis 
Positive: CD3 (partial), CD7, 
CD8, CD30+ in Large Cells, 
TIA-1, Granzyme B, β-F1 
Negative: CD2, CD4, CD5, 
CD56 








ND 168 mo ND AWD 
Allogeneic  46 F Ulcerated nodule Positive: CD3, CD5, CD8, 
TIA-1, β-F1 







ND 24 mo ND AWD 
Allogeneic  31 M Necrotic 
ulcerations 
Positive: CD3, CD7+ CD8, 
CD45RA, TIA-1, β-F1 
Negative: CD4, CD5, CD30, 
CD56, Granzyme B 
Hyper-CVAD, BXT, 
PUVA, 
ND 84 mo ND AWD 
Allogeneic  63 M Patches, tumor Positive: CD3, CD7, CD45RA, 
TIA-1 subset, Granzyme B, β-
F1 
Negative: CD4, CD5, CD8, 
CD56  
CHOEP, TSEBT, ND 10 mo ND Dead 
Allogeneic  21 F Ulcerated plaque Positive: CD2, CD3, CD7, 
CD8 (weak), CD45RA, CD56, 
TIA-1, Granzyme B, β-F1 
(weak) 




Gem, PTX, romi, 
XRT 







47 M Disseminated 
ulcerative 
plaques 
Positive: CD3, CD8, TIA-1, 
granzyme B 
Negative: CD4, CD30, 












1 Autologous  38 M Multiple ulcerated 
erythematous 
lesions 
Positive: CD3, CD8, TIA-1 




CHASE, MCEC CR 46 mo N/A Developed treatment 
related AML, treated 
with umbilical cord 
blood transplant, 
followed by relapse, 
allogeneic SCT, patient 





CD3+   CD8+   CD4 -   
CD2 -   CD5 -   CD7 -   
TIA1+   CD56 -   EBER -   
Table 6: Treatment Alogrithm for CD8+ PCAETCL  
Initial therapy for disseminated disease 
CHOP, EPOCH, or other aggressive lymphoma regimen 
If no complete remission achieved, second line regimens 
Gemcitabine regimens 
Pralatrexate 
Brentuximab vedotin (if CD30+) 
Nelarabine, alemtuzumab, bendamustine 
Total skin electron beam radiotherapy  
If complete remission achieved 
Allogeneic stem cell transplant if patient is a candidate and has a donor 
(consider total skin electron beam radiotherapy prior to transplant) 



















Figure 2: CD8+ PCAETL atypical lymphocytes involving hair follicle  
 
Figure 3: Variable presentations of CD8+ PCAETL (A) focal ulcer (Patient #2), (B) 








 A rapidly progressing form of cytotoxic CD8 positive T-Cell Lymphoma 
was first described in 1990 by Agnarsson et al118, and named formally by Berti et 
al119 in 1999. In the 1999 case series, 17 patients with CD8+ cutaneous 
lymphomas were described, including a subset of patients with epidermotropic, 
rapidly progressing, treatment resistant, and ultimately fatal disease. Since then, 
there have been over 100 cases described in the literature including the largest 
case series to date published in 2017112,129. Difficulty in distinguishing CD8+ 
PCAETL from its more indolent imitators can lead to delayed diagnosis and poor 
outcomes, including published reports of patients dying prior to initiation of 
treatment112,116. Additionally, the progressive nature and extreme severity of the 
disease has led to a paucity of data regarding effective treatments. There is little 
data documenting the response to novel agents such as HDAC inhibitors and 
targeted antibody toxins. 
In the largest case study to date, Guitart et al. observed that allogeneic 
stem cell transplantation was the sole therapy that resulted in sustained 
response of any type112. In order to define the role of transplantation in the 
treatment of CD8+ PCAETL we identified 18 published cases of stem cell 
transplantation. A summary of the findings can be found in Table 5. Of these, 3 
occurred prior to the 2005 WHO classification. Of these 18 cases, 6 were 
autologous bone marrow or peripheral blood stem cell transplants, 11 were 
allogeneic stem cell transplants, and 2 were bone marrow transplants of 




the same patient, an autologous transplantation followed by an allogeneic 
transplant. The number of prior therapies ranged from 1-11, with a median of 3 
prior therapies. Systemic chemotherapy was utilized in 16/18 cases, including all 
cases after 1990. Complete or partial response was achieved in 13 patients, 3 
had no response, while 2 patients lacked documentation of response. Of the 13 
responding patients, only 2 had a reported relapse, though follow up information 
was not reported or incomplete in some studies112,118,125,126. Autologous 
transplantation resulted in durable response in 2/6 cases, while allogeneic 
transplantation resulted in durable response in 9/11 cases. One case was 
complicated by treatment related acute myelogenous leukemia which was 
treated with an umbilical cord blood transplant and a second allogeneic 
peripheral blood HSCT. The overall survival among patients receiving any type of 
transplant was 55.6% at a median follow up of 24 months.  
In our series of 8 patients with CD8+ PCAETL, 4 underwent allogeneic 
stem cell transplantation, including one case of umbilical cord blood transplant. 
One patient received infusion of donor lymphocytes for post transplant relapse, 
and achieved remission with Brentuximab. All patients who received a transplant 
were alive at the last follow up. No patients achieved durable remission with any 
single or multi-agent systemic chemotherapy. Single agent HDAC inhibitor 
therapy did not result in responses. A notable finding was the relative activity of 
the novel agents pralatrexate and brentuximab vedotin in relapsed and refractory 
patients. Brentuximab vedotin, an antibody-drug-conjugate directed against the 




positive patients and resulted in stable disease in a CD30 negative patient by 
conventional immunohistochemistry.  
Our limited series and review of the literature outline clinical challenges in 
the treatment of CD8+ PCAETL with conventional chemotherapeutic approaches. 
Unfortunately, many patients demonstrate resistance to multiple chemotherapy 
agents and regimens; however, the advent of new therapy modalities and the 
increased use of hematopoietic stem cell transplant has led to improved 
outcomes and survival. Table 6 outlines a treatment algorithm for PCAETCL 
based on available limited evidence. Our findings support implementation of an 
aggressive strategy early in the course of treatment, including the consideration 
of allogeneic stem cell transplant and donor search at the time of diagnosis. 
Further, the use of novel agents earlier in the course of therapy remains to be 
defined. Future studies should include molecular and genetic profiling of the 
tumor in an effort to identify mutations and altered pathways that may lead to a 
precision medicine approach for these patients.  
Clinical Practice Points:  
 CD8+ PCAETL is a rare, rapidly progressive, and deadly disease, for 
which no formalized treatment strategy exists, though HSCT have been 
suggested a potential curative therapy 
 
 In this case series , four of eight patients underwent an allogeneic stem 
cell transplant, resulting in a complete and durable remission in two 
patients. All patients who received a transplant were alive at their last 
follow up (median 45.5 months). 
 
 Brentuximab and pralatrexate demonstrated significant anti-disease 
activity in relapse and resistant cases of CD8+ PCAETL, with overall 





 Our study suggests that more aggressive use of HSCT, including early 
consideration and donor search at time of diagnosis, may result in better 
outcomes. 
 
 Further research is necessary to better understand the activity of novel 
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